The Week in Review: China Puts CAS in Charge of Stem Cell Initiative

CAS announced a research platform to advance stem cell and regenerative medicine research; Tian Xu, PhD, and Fudan University’s Mouse Functional Genome Project were featured as examples of the sea turtle phenomenon; Fosun Pharma paid $102.4 million for a 75% stake in Aleph Biomedical, a vaccine maker; Jolly Pharma expects to raise $71.3 million in its ChiNext IPO; Qianhong Biopharma announced plans to IPO on the Shenzhen exchange; Huahai Pharma will supply APIs and intermediates to the Sandoz division of Novartis; Aushon BioSystems will collaborate with Peking University Cancer Hospital for cancer diagnostic markers; Takeda Pharma began a Phase III trial in China of a DPP-4 treatment for type 2 diabetes; and NS8 announced the China launch of a generic version of the antidepressant Zoloft. More details…. Stock Symbols: (SZ: 300181) (SZ: 002550) (SH: 600521) (NYSE: NVS) (TSE: 4502)